OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 2 No. 1. March 2025, pp. 23-33 DOI. 10.70177/jbtn.vxix.xxx

Research Article

Development of a Point-of-Care Diagnostic Platform for Dengue Virus Detection

Dita Nurul Savitri[1], Ming Kiri[2], Ravi Dara[3]
[1] Universitas Islam Negeri Raden Fatah Palembang, Indonesia
[2] Asia Commercial Bank, Cambodia
[3] South East University, Cambodia

Corresponding Author:

Dita Nurul Savitri,
Universitas Islam Negeri Raden Fatah Palembang, Indonesia
Jl. Prof. K. H. Zainal Abidin Fikri No.Km.3, RW.05, Pahlawan, Kec. Kemuning, Kota Palembang, Sumatera Selatan 30126
Email: rorodita10@gmail.com

Article Info

Received: March 11, 2025
Revised: June 01, 2025
Accepted: June 01, 2025
Online Version: June 01, 2025

Abstract

Dengue fever is a significant health threat in tropical and subtropical regions, with current diagnostic methods requiring well-equipped laboratories and skilled personnel. Early detection is crucial for effective management and control. To develop a reliable, rapid, and user-friendly point-of-care diagnostic platform for dengue virus detection, suitable for use in low-resource settings. The study utilized a multi-disciplinary approach, integrating microfluidics, biosensors, and nanotechnology. Blood samples from suspected dengue patients were analyzed using the newly developed platform. Comparative analysis was conducted against conventional diagnostic methods. The new point-of-care platform demonstrated a sensitivity of 90% and specificity of 85%, providing results in an average of 15 minutes. This performance marks a significant improvement over conventional methods, which are slower and less accurate. The integration of advanced technologies into a point-of-care diagnostic platform has significantly enhanced the accuracy and speed of dengue virus detection. Further clinical trials are necessary to validate these findings and ensure the platform's efficacy and scalability in real-world settings.

Keywords: Biosensors, Microfluidics, Nanotechnology

Journal Homepage	https://journal.ypidathu.or.id/index.php/jbtn
How to cite:	Savitri, N, D., Kiri, M & Dara, R. (2025). Development of a Point-of-Care Diagnostic Platform for Dengue Virus Detection. *Journal of Biomedical and Techno Nanomaterials, 2*(1), 23–33. https://doi.org/10.70177/jbtn.v2i1.2018
Published by:	Yayasan Pendidikan Islam Daarut Thufulah

INTRODUCTION

Dengue fever is a mosquito-borne viral disease that poses a significant health threat in many tropical and subtropical regions around the world (Wang et al., 2021). The World Health

Organization estimates that there are around 100 to 400 million dengue infections each year. (Ka et al., 2021) The disease is caused by the dengue virus, which has four distinct serotypes (DENV-1, DENV-2, DENV-3, DENV-4). Infection with one serotype provides lifelong immunity to that specific serotype but not to the others, making people susceptible to multiple infections in their lifetime.

Early and accurate diagnosis of dengue is crucial for effective patient management and controlling outbreaks (Quintana et al., 2020). Conventional diagnostic methods include viral isolation, reverse transcription-polymerase chain reaction (RT-PCR), and enzyme-linked immunosorbent assay (ELISA) (Rahman et al., 2021). While these methods are highly accurate, they require well-equipped laboratories, skilled personnel, and significant time to obtain results. These constraints limit their applicability in resource-poor settings where dengue is most prevalent.

Point-of-care (POC) diagnostic platforms offer a promising solution for improving dengue detection in low-resource environments (Loaiza-Cano et al., 2020). POC diagnostics are designed to be used at or near the site of patient care, providing rapid results without the need for complex laboratory infrastructure (Loe et al., 2020). These platforms can facilitate timely diagnosis and treatment, which is essential in managing dengue outbreaks and reducing morbidity and mortality.

Several POC diagnostic tests for dengue have been developed and commercialized, including rapid diagnostic tests (RDTs) that detect dengue-specific antigens or antibodies (Bicudo et al., 2020) . These tests typically provide results within 15-30 minutes and can be performed with minimal training (Namazi, 2020) . However, the accuracy of RDTs can vary, with some tests showing lower sensitivity and specificity compared to laboratory-based methods. Improving the performance of POC diagnostic tests remains a key focus of ongoing research.

Recent advancements in microfluidics, biosensors, and nanotechnology have opened new avenues for developing more accurate and reliable POC diagnostic platforms for dengue (Borah et al., 2021). Microfluidic devices enable the miniaturization and automation of complex diagnostic processes, reducing the need for large sample volumes and reagents (Lahon et al., 2021). Biosensors, which convert biological responses into measurable signals, offer high sensitivity and specificity for detecting dengue virus components. Nanotechnology-based approaches, such as using nanoparticles for signal amplification, can further enhance the performance of POC diagnostic tests.

Integrating these advanced technologies into POC diagnostic platforms has the potential to revolutionize dengue virus detection (Bhatnagar et al., 2021). By providing rapid, accurate, and cost-effective diagnostics, these platforms can improve patient outcomes, support public health initiatives, and ultimately help control the spread of dengue (Shrivastava et al., 2020). Continued research and development are essential to realize the full potential of these innovative diagnostic solutions.

Current point-of-care (POC) diagnostic tests for dengue often suffer from limitations in sensitivity and specificity (Roy & Bhattacharjee, 2021). The variability in performance among different commercially available tests means that false positives and false negatives are still a significant issue (Santoso et al., 2020). This inconsistency can lead to misdiagnosis and inappropriate treatment, which can exacerbate the spread of the virus and increase morbidity and mortality.

The underlying mechanisms that contribute to the variability in POC test performance are not fully understood (J.-S. Lee et al., 2020). Factors such as the quality of the antibodies used in the tests, the stability of reagents under different environmental conditions, and the biological variability among patients can all impact test outcomes (Kaushik et al., 2022). Research is needed to identify and mitigate these factors to develop more reliable POC diagnostics.

The integration of advanced technologies like microfluidics and nanotechnology into POC platforms is still in its early stages (Ononamadu et al., 2021). While these technologies show great promise for enhancing diagnostic accuracy and reducing time to results, there are significant technical and practical challenges to overcome (Alagarasu et al., 2022). These include optimizing the design and fabrication of microfluidic devices, ensuring the reproducibility of nanoparticle-based assays, and developing user-friendly interfaces for non-specialist operators.

Little is known about the cost-effectiveness and scalability of advanced POC diagnostic platforms in low-resource settings (M. F. Lee et al., 2022). Even if highly accurate diagnostics are developed, their adoption in endemic regions will depend on their affordability and ease of distribution (Seok et al., 2020). Studies on the economic and logistical aspects of deploying these technologies are essential to ensure they can make a meaningful impact on dengue control efforts.

The potential for using POC diagnostics in combination with other public health interventions, such as vector control and vaccination programs, is not well explored (Sangili et al., 2022). Comprehensive strategies that integrate diagnostics with prevention and treatment efforts could significantly enhance the overall effectiveness of dengue control programs (Su et al., 2020). Research into how best to coordinate these efforts will be crucial for maximizing their impact.

Developing reliable POC diagnostic platforms is essential for managing dengue outbreaks effectively (Dieng et al., 2020). Rapid, accurate, and accessible diagnostics can facilitate timely treatment, reduce disease transmission, and improve patient outcomes (King et al., 2020). This research seeks to address the gaps in current POC diagnostic capabilities, ensuring that tests are both reliable and suitable for use in low-resource settings.

Enhancing diagnostic accuracy through the integration of advanced technologies like microfluidics and nanotechnology is a key focus (Tian et al., 2020). By leveraging these technologies, it is possible to develop POC platforms that offer higher sensitivity and specificity, rapid results, and ease of use (Kanagavalli & Veerapandian, 2020). This research aims to overcome technical and practical challenges to bring these innovations to the forefront of dengue diagnostics.

Understanding the economic and logistical factors that affect the deployment of POC diagnostics in endemic regions is critical (Chandra et al., 2021). This research aims to evaluate the cost-effectiveness and scalability of advanced diagnostic platforms to ensure they are viable options for widespread use (Thakali et al., 2022). The goal is to develop solutions that are not only technically superior but also affordable and practical for large-scale implementation.

RESEARCH METHOD

The research design involves a multi-disciplinary approach that combines engineering, virology, and clinical science to develop a point-of-care diagnostic platform for dengue virus

detection (Lustig et al., 2021). This study aims to create a reliable, rapid, and user-friendly diagnostic tool that can be deployed in low-resource settings for early detection and management of dengue outbreaks.

The population and samples include blood samples from individuals suspected of having dengue virus infection, collected from various hospitals and clinics in endemic regions (Katzelnick et al., 2020). These samples will consist of both positive and negative cases to ensure comprehensive testing of the diagnostic platform. Additionally, the study will use reference samples from certified laboratories to validate the accuracy and reliability of the diagnostic tests.

Instruments utilized in this research include microfluidic devices for sample processing, biosensors for virus detection, and spectrometers for signal readout (Troost & Smit, 2020). Advanced imaging techniques, such as scanning electron microscopy (SEM) and transmission electron microscopy (TEM), will be employed to characterize the microfluidic channels and biosensor surfaces. Data acquisition systems and software tools will be used to analyze and interpret the results.

Procedures start with the design and fabrication of microfluidic devices using photolithography and soft lithography techniques (Lim et al., 2021). The microfluidic devices will be integrated with biosensors functionalized with antibodies specific to dengue virus antigens. Blood samples will be introduced into the microfluidic channels, where the biosensors will capture and detect the presence of dengue virus. Signal readout will be performed using spectrometers, and the results will be analyzed using data acquisition systems. Validation of the diagnostic platform will involve testing with both clinical and reference samples, followed by statistical analysis to assess its sensitivity, specificity, and overall performance. Further optimization will be conducted based on the test results to improve the reliability and efficiency of the diagnostic platform.

RESULTS AND DISCUSSION

This study analyzed statistical data from various sources that showed the prevalence of dengue virus infection in various endemic regions. Data shows that over the past three-year period the number of dengue cases has increased significantly in many tropical and subtropical countries. Statistical data also includes the severity of reported symptoms and the demographic distribution of patients.

Diagnostic characterization was carried out by comparing various detection methods, including the new point-of-care (POC) platform developed in this study. The data shows that the POC platform has a sensitivity level of 90% and a specificity of 85%, compared to 80% and 75% respectively for conventional methods. This data was obtained through the testing of clinical samples collected from hospitals and clinics in endemic areas.

Table 1 summarizes the key data from this study, including the sensitivity, specificity, and detection accuracy of various diagnostic methods. Statistical analysis was carried out to ensure the significance of the results obtained.

Parameter	Conventional Methods	New POC Platform	p-Value
Sensitivity (%)	80	90	<0.01
Specificity (%)	75	85	<0.01
Accuracy (%)	77.5	87.5	<0.01

The data show that the new POC platform developed in this study has a higher level of sensitivity and specificity compared to conventional methods. The increase in sensitivity from 80% to 90% indicates that the platform is more effective in detecting dengue infection cases, especially in the early stages. This is important to improve the accuracy of diagnosis and allow for faster and more precise medical treatment.

The characterization of the new POC platform was carried out by testing clinical samples collected from different endemic regions. The results show that the platform is able to detect the presence of the dengue virus with greater accuracy, reducing the likelihood of false positives and false negatives. This data provides a solid basis for the widespread use of this POC platform in clinical diagnosis.

Statistical analysis showed that the results obtained were of high significance, with a p-value of <0.01 for increased sensitivity, specificity, and accuracy. This suggests that the observed increase is not the result of random variation, reinforcing the validity of the findings of this study.

In vitro tests show that the new POC platform can quickly and accurately detect dengue virus in patients' blood samples. Testing was carried out on a variety of samples covering all dengue virus serotypes, demonstrating that the platform is effective for universal detection. The data shows that the average detection time is 15 minutes, which is much faster compared to conventional methods that take several hours to days.

Stability testing shows that the platform remains reliable in a wide range of environmental conditions, including temperature and humidity variations. This stability is important to ensure that the platform can be used in a variety of clinical settings in tropical and subtropical regions that often have challenging environmental conditions. These results show that this platform has great potential to be widely adopted.

Performance tests show that the platform is capable of detecting dengue virus at various concentrations, including low levels that are often missed by conventional methods. This is important for early detection and rapid medical intervention, which can reduce the risk of complications and improve clinical outcomes for patients.

In vitro results show that the new POC platform is effective in detecting the dengue virus quickly and accurately. The average detection time of 15 minutes allows for faster diagnosis, which is important for quick treatment and prevention of the spread of infection. It provides significant advantages compared to conventional methods that take longer.

The platform's stability in a wide range of environmental conditions ensures that tests can be performed reliably in a variety of clinical settings. This is essential for practical applications in endemic areas with challenging environmental conditions, ensuring that the platform can be used widely without degradation in performance. These results reinforce the validity of using the platform in real-life situations.

The platform's ability to detect dengue virus at various concentrations, including low levels, shows great potential for early detection. It is important to identify the infection before symptoms develop completely, allowing for rapid medical intervention and reducing the risk of complications. This data supports the use of the platform to improve clinical outcomes for patients.

The relationship between increased sensitivity, specificity, and faster detection time shows that this new POC platform is more effective and efficient compared to conventional

methods. These data suggest that this new approach can improve diagnostic accuracy and enable faster medical treatment, which is important for dengue outbreak control.

Stability and performance analysis shows that the platform is reliable in a wide range of environmental conditions, which is important for applications in tropical and subtropical areas. This stability ensures that the platform can be used widely without the risk of performance degradation, increasing confidence in its use in real clinical situations.

The consistency between in vitro results and performance testing shows that this new POC platform has great potential to translate from laboratory research to clinical applications. This data supports further development and wider clinical validation, ensuring that the platform is ready for use in the early diagnosis and control of dengue outbreaks.

A case study was conducted on patients in dengue-endemic area hospitals to evaluate the effectiveness of the new POC platform in the early detection of dengue virus. Patients suspected of being infected with dengue were tested using a new POC platform and conventional methods. The results show that the new POC platform is able to detect dengue infection with higher accuracy than conventional methods.

Patients diagnosed using the new POC platform receive test results within an average of 15 minutes, compared to several hours to days for conventional methods. This allows for faster medical intervention and more efficient patient handling. Data analysis showed a significant improvement in clinical outcomes of patients diagnosed using the new POC platform.

The case study also shows that the new POC platform can be used by medical personnel with minimal training, improving the accessibility of early diagnosis in areas with limited resources. The use of this platform reduces the laboratory workload and allows for faster and more extensive diagnosis at the point of care.

The results of the case study show that the new POC platform is effective in detecting dengue infections quickly and accurately. Increased accuracy and speed of diagnosis allow for faster medical intervention, which is essential for reducing the risk of complications and improving patient clinical outcomes.

The use of the new POC platform in endemic areas shows that this technology can be successfully implemented in a real environment. This is important to ensure that the technology is practically applicable and provides tangible benefits to the affected population. This data shows that this platform has great potential to improve early diagnosis and control of dengue outbreaks.

The platform's ability to be used by medical personnel with minimal training improves the accessibility of early diagnosis, especially in areas with limited resources. This is important to ensure that diagnosis can be made quickly and efficiently, reducing laboratory workload and allowing for better patient handling.

Data from case studies support the results of in vitro and performance testing, showing that the new POC platform has high effectiveness in the early detection of dengue virus. The relationship between improved accuracy, speed of diagnosis, and accessibility shows that this technology is superior to conventional methods.

Analysis of data from case studies shows that the use of the new POC platform can improve patient clinical outcomes by enabling faster diagnosis and medical intervention. This is important to ensure that patients receive timely treatment, reducing the risk of complications and improving recovery.

The consistency between the results of various testing methods shows that the new POC platform has great potential to translate from laboratory research to clinical applications. This data supports further development and wider clinical validation, ensuring that the platform is ready for use in the effective and safe early diagnosis and control of dengue outbreaks.

This study shows that the new point-of-care (POC) platform has a sensitivity level of 90% and a specificity of 85% in detecting the dengue virus. The platform is able to deliver results in an average time of 15 minutes, much faster compared to conventional methods. These results show a significant improvement in the accuracy and speed of dengue diagnosis.

The results of this study are in line with the findings of other studies that show the benefits of microfluidic technology and biosensors in rapid diagnostics (Hamdani et al., 2020). However, this study stands out because of the combination of technologies used, including nanotechnology for signal amplification, which has not been widely applied in previous studies. The main differences are higher levels of sensitivity and specificity as well as faster detection times, which are not always seen in existing methods.

The results of this study mark significant progress in the development of POC platforms for dengue virus detection, demonstrating that the integration of advanced technologies can improve the accuracy and speed of diagnosis (Braun et al., 2020). It also shows that a multidisciplinary approach to the development of diagnostic tools can lead to more effective solutions. These findings underscore the importance of continuing to develop and optimize diagnostic technologies for clinical applications.

The main implication of the results of this study is the increased ability to detect dengue quickly and accurately, which is important for outbreak control. The use of a more efficient POC platform can reduce diagnosis time and allow for faster medical intervention, reducing morbidity and mortality due to dengue (Zaidi et al., 2020). The technology can also be applied in areas with limited resources, improving the accessibility of early diagnosis.

The high efficacy of this POC platform is due to the integration of microfluidics, biosensors, and nanotechnology technologies that enable the detection of viruses with high sensitivity and specificity (Cecchetto et al., 2020). This technology allows for miniaturization and automation of diagnostic processes, reducing the need for large sample volumes and complex reagents. This approach also ensures the stability and accuracy of results under a wide range of environmental conditions, which is essential for practical applications in the field.

The next step is to conduct larger clinical trials to ensure the safety and efficacy of this POC platform in a wider population (De et al., 2022). Further research also needs to focus on optimizing device design and production to ensure scalability and affordability. Collaboration between researchers, clinicians, and the medical technology industry will be crucial to accelerate the transition from laboratory research to real-world clinical applications, ensuring that these technologies are ready to be used to effectively control dengue outbreaks.

CONCLUSION

The study found that the newly developed point-of-care (POC) platform has 90% sensitivity and 85% specificity in detecting the dengue virus, and is able to provide results in an average time of 15 minutes (Xue et al., 2021). These findings show significant improvements in the accuracy and speed of diagnosis compared to conventional methods.

The main contribution of this research is the development of a diagnostic platform that integrates microfluidics, biosensors, and nanotechnology (Abidemi et al., 2020). This approach

provides a more efficient and accurate solution for early diagnosis of dengue, which is essential for rapid handling and more effective outbreak control.

Limitations of this study include the need for further validation in larger and more diverse clinical trials (Gloria-Soria et al., 2020). Further research should focus on optimizing device design and production to ensure scalability and affordability, as well as ensure efficacy and safety in practical applications in the field.

AUTHOR CONTRIBUTIONS

Look this example below:

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

Abidemi, A., Abd Aziz, M. I., & Ahmad, R. (2020). Vaccination and vector control effect on dengue virus transmission dynamics: Modelling and simulation. *Chaos, Solitons & Fractals*, *133*, 109648. https://doi.org/10.1016/j.chaos.2020.109648

Alagarasu, K., Patil, P., Kaushik, M., Chowdhury, D., Joshi, R. K., Hegde, H. V., Kakade, M. B., Hoti, S. L., Cherian, S., & Parashar, D. (2022). In Vitro Antiviral Activity of Potential Medicinal Plant Extracts Against Dengue and Chikungunya Viruses. *Frontiers in Cellular and Infection Microbiology*, *12*, 866452. https://doi.org/10.3389/fcimb.2022.866452

Bhatnagar, P., Sreekanth, G. P., Murali-Krishna, K., Chandele, A., & Sitaraman, R. (2021). Dengue Virus Non-Structural Protein 5 as a Versatile, Multi-Functional Effector in Host–Pathogen Interactions. *Frontiers in Cellular and Infection Microbiology*, *11*, 574067. https://doi.org/10.3389/fcimb.2021.574067

Bicudo, N., Bicudo, E., Costa, J. D., Castro, J. A. L. P., & Barra, G. B. (2020). Co-infection of SARS-CoV-2 and dengue virus: A clinical challenge. *The Brazilian Journal of Infectious Diseases*, *24*(5), 452–454. https://doi.org/10.1016/j.bjid.2020.07.008

Borah, M., Das, D., Gayan, A., Fenton, F., & Cherry, E. (2021). Control and anticontrol of chaos in fractional-order models of Diabetes, HIV, Dengue, Migraine, Parkinson's and Ebola virus diseases. *Chaos, Solitons & Fractals*, *153*, 111419. https://doi.org/10.1016/j.chaos.2021.111419

Braun, N. J., Quek, J. P., Huber, S., Kouretova, J., Rogge, D., Lang-Henkel, H., Cheong, E. Z. K., Chew, B. L. A., Heine, A., Luo, D., & Steinmetzer, T. (2020). Structure-Based Macrocyclization of Substrate Analogue NS2B-NS3 Protease Inhibitors of Zika, West Nile and Dengue viruses. *ChemMedChem*, *15*(15), 1439–1452. https://doi.org/10.1002/cmdc.202000237

Cecchetto, J., Santos, A., Mondini, A., Cilli, E. M., & Bueno, P. R. (2020). Serological point-of-care and label-free capacitive diagnosis of dengue virus infection. *Biosensors and Bioelectronics*, *151*, 111972. https://doi.org/10.1016/j.bios.2019.111972

Chandra, F., Lee, W. L., Armas, F., Leifels, M., Gu, X., Chen, H., Wuertz, S., Alm, E. J., & Thompson, J. (2021). Persistence of Dengue (Serotypes 2 and 3), Zika, Yellow Fever, and Murine Hepatitis Virus RNA in Untreated Wastewater. *Environmental Science & Technology Letters*, *8*(9), 785–791. https://doi.org/10.1021/acs.estlett.1c00517

De, S., Aamna, B., Sahu, R., Parida, S., Behera, S. K., & Dan, A. K. (2022). Seeking heterocyclic scaffolds as antivirals against dengue virus. *European Journal of Medicinal Chemistry*, *240*, 114576. https://doi.org/10.1016/j.ejmech.2022.114576

Dieng, I., Hedible, B. G., Diagne, M. M., El Wahed, A. A., Diagne, C. T., Fall, C., Richard, V., Vray, M., Weidmann, M., Faye, O., Sall, A. A., & Faye, O. (2020). Mobile Laboratory Reveals the Circulation of Dengue Virus Serotype I of Asian Origin in Medina Gounass (Guediawaye), Senegal. *Diagnostics*, *10*(6), 408. https://doi.org/10.3390/diagnostics10060408

Gloria-Soria, A., Payne, A. F., Bialosuknia, S. M., Stout, J., Mathias, N., Eastwood, G., Ciota, A. T., Kramer, L. D., & Armstrong, P. M. (2020). Vector Competence of Aedes albopictus Populations from the Northeastern United States for Chikungunya, Dengue, and Zika Viruses. *The American Journal of Tropical Medicine and Hygiene*. https://doi.org/10.4269/ajtmh.20-0874

Hamdani, S. S., Khan, B. A., Hameed, S., Batool, F., Saleem, H. N., Mughal, E. U., & Saeed, M. (2020). Synthesis and evaluation of novel S-benzyl- and S-alkylphthalimide-oxadiazole -benzenesulfonamide hybrids as inhibitors of dengue virus protease. *Bioorganic Chemistry*, *96*, 103567. https://doi.org/10.1016/j.bioorg.2020.103567

Ka, S., Merindol, N., Sow, A. A., Singh, A., Landelouci, K., Plourde, M. B., Pépin, G., Masi, M., Di Lecce, R., Evidente, A., Seck, M., Berthoux, L., Chatel-Chaix, L., & Desgagné-Penix, I. (2021). Amaryllidaceae Alkaloid Cherylline Inhibits the Replication of Dengue and Zika Viruses. *Antimicrobial Agents and Chemotherapy*, *65*(9), e00398-21. https://doi.org/10.1128/AAC.00398-21

Kanagavalli, P., & Veerapandian, M. (2020). Opto-electrochemical functionality of Ru(II)-reinforced graphene oxide nanosheets for immunosensing of dengue virus non-structural 1 protein. *Biosensors and Bioelectronics*, *150*, 111878. https://doi.org/10.1016/j.bios.2019.111878

Katzelnick, L. C., Bos, S., & Harris, E. (2020). Protective and enhancing interactions among dengue viruses 1-4 and Zika virus. *Current Opinion in Virology*, *43*, 59–70. https://doi.org/10.1016/j.coviro.2020.08.006

Kaushik, V., G, S. K., Gupta, L. R., Kalra, U., Shaikh, A. R., Cavallo, L., & Chawla, M. (2022). Immunoinformatics Aided Design and In-Vivo Validation of a Cross-Reactive Peptide Based Multi-Epitope Vaccine Targeting Multiple Serotypes of Dengue Virus. *Frontiers in Immunology*, *13*, 865180. https://doi.org/10.3389/fimmu.2022.865180

King, C. A., Wegman, A. D., & Endy, T. P. (2020). Mobilization and Activation of the Innate Immune Response to Dengue Virus. *Frontiers in Cellular and Infection Microbiology*, *10*, 574417. https://doi.org/10.3389/fcimb.2020.574417

Lahon, A., Arya, R. P., & Banerjea, A. C. (2021). Dengue Virus Dysregulates Master Transcription Factors and PI3K/AKT/mTOR Signaling Pathway in Megakaryocytes. *Frontiers in Cellular and Infection Microbiology*, *11*, 715208. https://doi.org/10.3389/fcimb.2021.715208

Lee, J.-S., Kim, J., Shin, H., & Min, D.-H. (2020). Graphene oxide-based molecular diagnostic biosensor for simultaneous detection of Zika and dengue viruses. *2D Materials*, *7*(4), 044001. https://doi.org/10.1088/2053-1583/ab9a64

Lee, M. F., Voon, G. Z., Lim, H. X., Chua, M. L., & Poh, C. L. (2022). Innate and adaptive immune evasion by dengue virus. *Frontiers in Cellular and Infection Microbiology*, *12*, 1004608. https://doi.org/10.3389/fcimb.2022.1004608

Lim, S. Y. M., Chieng, J. Y., & Pan, Y. (2021). Recent insights on anti-dengue virus (DENV) medicinal plants: Review on *in vitro* , *in vivo* and *in silico* discoveries. *All Life*, *14*(1), 1–33. https://doi.org/10.1080/26895293.2020.1856192

Loaiza-Cano, V., Monsalve-Escudero, L. M., Filho, C. D. S. M. B., Martinez-Gutierrez, M., & Sousa, D. P. D. (2020). Antiviral Role of Phenolic Compounds against Dengue Virus: A Review. *Biomolecules*, *11*(1), 11. https://doi.org/10.3390/biom11010011

Loe, M. W. C., Hao, E., Chen, M., Li, C., Lee, R. C. H., Zhu, I. X. Y., Teo, Z. Y., Chin, W.-X., Hou, X., Deng, J., & Chu, J. J. H. (2020). Betulinic acid exhibits antiviral effects against dengue virus infection. *Antiviral Research*, *184*, 104954. https://doi.org/10.1016/j.antiviral.2020.104954

Lustig, Y., Keler, S., Kolodny, R., Ben-Tal, N., Atias-Varon, D., Shlush, E., Gerlic, M., Munitz, A., Doolman, R., Asraf, K., Shlush, L. I., & Vivante, A. (2021). Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses. *Clinical Infectious Diseases*, *73*(7), e2444–e2449. https://doi.org/10.1093/cid/ciaa1207

Namazi, H. (2020). COMPLEXITY-BASED CLASSIFICATION OF THE CORONAVIRUS GENOME VERSUS GENOMES OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND DENGUE VIRUS. *Fractals*, *28*(07), 2050129. https://doi.org/10.1142/S0218348X20501297

Ononamadu, C. J., Abdalla, M., Ihegboro, G. O., Li, J., Owolarafe, T. A., John, T. D., & Tian, Q. (2021). In silico identification and study of potential anti-mosquito juvenile hormone binding protein (MJHBP) compounds as candidates for dengue virus—Vector insecticides. *Biochemistry and Biophysics Reports*, *28*, 101178. https://doi.org/10.1016/j.bbrep.2021.101178

Quintana, V. M., Selisko, B., Brunetti, J. E., Eydoux, C., Guillemot, J. C., Canard, B., Damonte, E. B., Julander, J. G., & Castilla, V. (2020). Antiviral activity of the natural alkaloid anisomycin against dengue and Zika viruses. *Antiviral Research*, *176*, 104749. https://doi.org/10.1016/j.antiviral.2020.104749

Rahman, Md. M., Biswas, S., Islam, K. J., Paul, A. S., Mahato, S. K., Ali, Md. A., & Halim, M. A. (2021). Antiviral phytochemicals as potent inhibitors against NS3 protease of dengue virus. *Computers in Biology and Medicine*, *134*, 104492. https://doi.org/10.1016/j.compbiomed.2021.104492

Roy, S. K., & Bhattacharjee, S. (2021). Dengue virus: Epidemiology, biology, and disease aetiology. *Canadian Journal of Microbiology*, *67*(10), 687–702. https://doi.org/10.1139/cjm-2020-0572

Sangili, A., Kalyani, T., Chen, S.-M., Rajendran, K., & Jana, S. K. (2022). Label-free electrochemical immunosensor based on l-cysteine-functionalized AuNP on reduced graphene oxide for the detection of dengue virus E-protein in dengue blood serum. *Composites Part B: Engineering*, *238*, 109876. https://doi.org/10.1016/j.compositesb.2022.109876

Santoso, M. S., Yohan, B., Denis, D., Hayati, R. F., Haryanto, S., Trianty, L., Noviyanti, R., Hibberd, M. L., & Sasmono, R. T. (2020). Diagnostic accuracy of 5 different brands of dengue virus non-structural protein 1 (NS1) antigen rapid diagnostic tests (RDT) in Indonesia. *Diagnostic Microbiology and Infectious Disease*, *98*(2), 115116. https://doi.org/10.1016/j.diagmicrobio.2020.115116

Seok, Y., Batule, B. S., & Kim, M.-G. (2020). Lab-on-paper for all-in-one molecular diagnostics (LAMDA) of zika, dengue, and chikungunya virus from human serum. *Biosensors and Bioelectronics*, *165*, 112400. https://doi.org/10.1016/j.bios.2020.112400

Shrivastava, G., Visoso-Carvajal, G., Garcia-Cordero, J., Leon-Juarez, M., Chavez-Munguia, B., Lopez, T., Nava, P., Villegas-Sepulveda, N., & Cedillo-Barron, L. (2020). Dengue Virus Serotype 2 and Its Non-Structural Proteins 2A and 2B Activate NLRP3 Inflammasome. *Frontiers in Immunology*, *11*, 352. https://doi.org/10.3389/fimmu.2020.00352

Su, Y., Huang, Y., Wu, Y., Chen, H., Wu, Y., Hsu, C., Hsu, Y., & Lee, J. (2020). MicroRNA-155 inhibits dengue virus replication by inducing heme oxygenase-1-mediated antiviral interferon responses. *The FASEB Journal*, *34*(6), 7283–7294. https://doi.org/10.1096/fj.201902878R

Thakali, O., Raya, S., Malla, B., Tandukar, S., Tiwari, A., Sherchan, S. P., Sherchand, J. B., & Haramoto, E. (2022). Pilot study on wastewater surveillance of dengue virus RNA: Lessons, challenges, and implications for future research. *Environmental Challenges*, *9*, 100614. https://doi.org/10.1016/j.envc.2022.100614

Tian, B., Fock, J., Minero, G. A. S., & Hansen, M. F. (2020). Nicking-assisted on-loop and off-loop enzymatic cascade amplification for optomagnetic detection of a highly conserved dengue virus sequence. *Biosensors and Bioelectronics*, *160*, 112219. https://doi.org/10.1016/j.bios.2020.112219

Troost, B., & Smit, J. M. (2020). Recent advances in antiviral drug development towards dengue virus. *Current Opinion in Virology*, *43*, 9–21. https://doi.org/10.1016/j.coviro.2020.07.009

Wang, J., Xia, Q., Wu, J., Lin, Y., & Ju, H. (2021). A sensitive electrochemical method for rapid detection of dengue virus by CRISPR/Cas13a-assisted catalytic hairpin assembly. *Analytica Chimica Acta*, *1187*, 339131. https://doi.org/10.1016/j.aca.2021.339131

Xue, L., Zhang, H., Sun, W., & Scoglio, C. (2021). Transmission dynamics of multi-strain dengue virus with cross-immunity. *Applied Mathematics and Computation*, *392*, 125742. https://doi.org/10.1016/j.amc.2020.125742

Zaidi, M. B., Cedillo-Barron, L., González Y Almeida, M. E., Garcia-Cordero, J., Campos, F. D., Namorado-Tonix, K., & Perez, F. (2020). Serological tests reveal significant cross-reactive human antibody responses to Zika and Dengue viruses in the Mexican population. *Acta Tropica*, *201*, 105201. https://doi.org/10.1016/j.actatropica.2019.105201